Patents by Inventor Julio A. Munoz

Julio A. Munoz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110118239
    Abstract: A novel scalable synthesis for the preparation of 7-(3-pyridinyI)-1,7-diazaspiro[4.4)nonane has been developed, and 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane salts have been formed with succinic acid and oxalic acid. Additionally, 7-(3-pyridinyl)-1,7-diaza-spiro[4.4]nonane has been separated into its stereoisomers via resolution with L and D di-p-toluoyltartaric acids, giving (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane of high enantiomeric purity. Numerous solid salts of the resulting (R)- and (S)-7-(3-pyridinyl)-1,7-diazaspiro[4.4}nonane have been prepared. Methods for the preparation of the racemic and enantiomeric salts, pharmaceutical compositions comprising such salts, and uses thereof are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.
    Type: Application
    Filed: January 15, 2009
    Publication date: May 19, 2011
    Applicant: Targacept, Inc.
    Inventors: Jessica Beaver, Scott Breining, Gary Maurice Dull, Gregory J. Gatto, John Genus, Jacob Mathew, Julio A. Munoz, Inigo Pfeiffer, Steve M. Ttoler, James Wamsley, Jianxun Xie
  • Publication number: 20100249196
    Abstract: Phosphoric acid, edisylic acid (1,2-ethanedisulfonic acid), citric acid, orotic acid (uracil-6-carboxylic acid), R-mandelic acid, sulfuric acid, 1,5-naphthalenedisulfonic acid, D-aspartic acid, and lysine monohydrochloride salts of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine, and methods for their preparation, pharmaceutical compositions comprising said salts, and use, are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.
    Type: Application
    Filed: May 8, 2007
    Publication date: September 30, 2010
    Applicants: ASTRAZENECA AB, TARGACEPT, INC.
    Inventors: Martin Hans Bohlin, Gary M. Dull, Caroline Eriksson, Craig H. Miller, Julio A. Munoz, Tesfai Sebhatu
  • Publication number: 20100048643
    Abstract: Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.
    Type: Application
    Filed: October 29, 2009
    Publication date: February 25, 2010
    Inventors: Gary M. Dull, Julio A. Munoz
  • Publication number: 20090062321
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
    Type: Application
    Filed: November 4, 2008
    Publication date: March 5, 2009
    Applicant: TARGACEPT, INC.
    Inventors: Julio A. Munoz, John Genus, James R. Moore
  • Publication number: 20090048290
    Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 19, 2009
    Inventors: Merouane Bencherif, Lisa Benson, Gary Maurice Dull, Nikolai Fedorov, Gregory J. Gatto, John Genus, Kristen G. Jordan, Jacob Mathew, Anatoly A. Mazurov, Lan Miao, Julio A. Munoz, Inigo Pfeiffer, Sondra Pfeiffer, Teresa Y. Phillips
  • Patent number: 7459469
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: December 2, 2008
    Assignee: Targacept, Inc.
    Inventors: Julio A. Munoz, John Genus, James R. Moore
  • Publication number: 20080249142
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine compound) or to another pharmaceutically acceptable salt form.
    Type: Application
    Filed: June 19, 2008
    Publication date: October 9, 2008
    Applicant: Targacept, Inc.
    Inventors: Gary Maurice Dull, Julio A. Munoz, John Genus, James R. Moore
  • Publication number: 20070265314
    Abstract: Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.
    Type: Application
    Filed: May 8, 2007
    Publication date: November 15, 2007
    Inventors: Gary Dull, Julio Munoz
  • Publication number: 20060122238
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
    Type: Application
    Filed: November 9, 2005
    Publication date: June 8, 2006
    Inventors: Gary Dull, Julio Munoz, John Genus, James Moore
  • Publication number: 20060122237
    Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
    Type: Application
    Filed: November 9, 2005
    Publication date: June 8, 2006
    Inventors: Julio Munoz, John Genus, James Moore
  • Patent number: 5179228
    Abstract: Improvements to a method for preparing N-phosphonomethylglycyne by oxidation of N-phosphonomethyliminodiacetic acid. N-phosphonomethylglycine may be obtained by oxidation of N-phosphonomethyliminodiacetic acid with O.sub.2 or with an oxygen-containing gas, in the presence of a noble metal catalyst on activated carbon. To avoid the catalyst losses, the improvements of the invention consist in a pressure scavaging with N.sub.2, after completion of the oxidation reaction. Owing to such treatment, the catalyst losses are reduced from 30% to 1%, making the processing economically viable on a large industrial scale. The recovered catalyst holds its catalytic activity and may be reused at least 20 consecutive times. N-phosphonomethylglycine is a herbicide of extended application.
    Type: Grant
    Filed: December 18, 1991
    Date of Patent: January 12, 1993
    Assignee: Ercros S.A.
    Inventors: Juan L. Martin Ramon, Julio Munoz Madronero
  • Patent number: 5131415
    Abstract: The present invention relates to a process for providing a tobacco extract. A tobacco material is provided in contact with an extraction solvent. The temperature of the tobacco material and liquid extraction solvent is reduced to below the freezing point thereof to provide a frozen mixture. The temperature of the frozen mixture is then raised to provide a melted portion including the tobacco extract within the liquid extraction solvent. The extract within the solvent preferably has a high soluble solids content (e.g., at least 10 percent by weight of the total weight of the melted portion). If desired, the tobacco extract within the extraction solvent can be further treated (e.g., chemically or physically) to provide or isolate flavorful and aromatic tobacco-derived components of tobacco extract.
    Type: Grant
    Filed: April 4, 1991
    Date of Patent: July 21, 1992
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Julio A. Munoz, Lila H. O'Connor